skip to Main Content

Board of Directors

Allen Baharaff

Mr. Baharaff is the co-​founder of Galmed, and has served as CEO since 2012, and President as of 2015. Previously, he held a number of senior executive positions, including SVP at Isramex Projects Ltd., and Managing Director of T+M Trusteeship & Management. He also serves as a Director of the Tel-​Aviv Museum of Arts and Executive Director at The Rubin Museum.
Mr. Baharaff holds a Bachelor of Science degree from the University of London (LSE) and LLB and MA degrees from Cambridge University. Since 1993, Mr. Baharaff has been a member of the Israel Bar Association.

Carol L. Brosgart, M.D.

Dr. Brosgart has served as a member of Galmed’s board of directors since 2017. Dr. Brosgart served as a member of Tobira Therapeutics’s Board of Directors from 2009 until it was acquired by Allergan in 2016. She is now a consultant to Allergan and a number of biotech­nology companies in the areas of liver disease and infec­tious disease. Dr. Brosgart currently serves on the Steering Committee of the National Viral Hepatitis Roundtable, the Executive Committee of the Forum for Collaborative Research, and the Steering Committee of the HBV Cure Group at the Forum. She is active in the public policy arena for AASLD and IDSA/​HIVMA.
Dr. Brosgart served as Senior Advisor on Science and Policy to the Division of Viral Hepatitis at the CDC and to the Viral Hepatitis Action Coalition at the CDC Foundation from 2011 to 2013. Dr. Brosgart has also served as a member on the faculty of the School of Medicine at the University of California, San Francisco for the past three decades, where she is a Clinical Professor of Medicine, Biostatistics and Epidemiology in the Division of Global Health and Infectious Diseases. From 2011 until 2011, Dr. Brosgart served as Chief Medical Officer at biotech­nology company Alios BioPharma, Inc. Prior to Alios, Dr. Brosgart served as Senior Vice President and Chief Medical Officer of Children’s Hospital & Research Center in Oakland, California, from 2009 until February 2011.
Previously, she served for eleven years, from 1998 until 2009, at the biophar­ma­ceu­tical company Gilead Sciences, Inc., where she held a number of senior management roles, most recently as Vice President, Public Health and Policy and earlier as Vice President, Clinical Research and Vice President, Medical Affairs and Global Medical Director, Hepatitis. She led the clinical devel­opment of a number of agents at Gilead, including Viread and Hepsera. Prior to Gilead, Dr. Brosgart worked for more than 20 years in clinical care, research and teaching at several Bay Area medical centers. She was the founder and Medical Director of the East Bay AIDS Center at Alta Bates Medical Center in Berkeley, California, from 1987 until 1998 and served as the Medical Director of Central Health Center, Oakland, California, of the Alameda County Health Care Services Agency.
Dr. Brosgart has also served on the boards of privately held companies and public, not-​for-​profit domestic and global health organi­za­tions. Dr. Brosgart received a B.S. in Community Medicine from the University of California, Berkeley and received an M.D. from the University of California, San Francisco. Her residency training was in pediatrics, public health and preventive medicine at UCSF and UC Berkeley School of Public Health. She has published exten­sively in the areas of HIV, HBV, CMV, and liver disease.

David Sidransky, M.D.
Lead Independent Director

Dr. David Sidransky, has served as a member of Galmed’s board of directors since 2014. Dr. Sidransky is a renowned oncol­ogist and research scientist who was profiled by TIME magazine in 2001 as one of the top physi­cians and scien­tists in America. He is widely recog­nized for his work with early detection of cancer. Dr. Sidransky serves as the Director of the Head and Neck Cancer Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, and is a Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at John Hopkins University and Hospital.
He has authored more than 500 peer-​reviewed publi­ca­tions, and has contributed to more than 60 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotech­nology companies and holds numerous biotech­nology patents. He has been the recipient of numerous awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians, and the 2004 Hinda Rosenthal Award and 2017 Team Award presented by the American Association of Cancer Research. Dr. Sidransky previ­ously served as Vice Chairman of the Board of Directors of ImClone.
He is Chairman of the Board of Advaxis Inc, Champions Oncology, and Tamir Biotechnology, and is on the Board of Directors of Rosetta Genomics Ltd and Orgenesis. He is a current and previous member of scien­tific advisory boards of corpo­ra­tions and insti­tu­tions, including Amgen, MedImmune, Roche and Veridex, LLC (a Johnson & Johnson diagnostic company). In addition, Dr. Sidransky served as Director of The American Association for Cancer Research from 2005 to 2008. He received his B.A. from Brandeis University and his M.D. from the Baylor College of Medicine.

Amir Poshinski

Amir Poshinski is an entre­preneur with over 20 years’ management and leadership experience across multiple indus­tries, including technology, biotech­nology, banking and real estate. Mr. Poshinski is the owner of DAP Holdings where since 2010 he acts as a management consultant and strategic advisor to global companies. Mr. Poshinski currently serves on the advisory board of Benson Oak Ventures, a venture focused fund, as well as several other private companies. Prior to 2010, Mr. Poshinski served as Deputy CEO of Primsa Investment House, which at the time was Israel’s largest investment house, Deputy CEO of Discount Mortgage Bank, the real estate lending arm of one of Israel’s largest banks, VP of Marketing of Comverse, a telecom­mu­ni­ca­tions software company that was listed on Nasdaq, VP Marketing, Sales and Advertising of Mifal Hapayis, Israel’s national lottery, and VP and Deputy CEO of the Economic Company of the Local Authority. Mr. Poshinski previ­ously served on the boards of TAS-​AGT (a TATA joint venture), Excellence Nessuah Mutual Funds, and Therapix Biosciences as well as several other private companies. Mr. Poshinski holds a B.A. in Business Administration and Marketing from the New York Institute of Technology.

Shmuel Nir

Shmuel Nir, has served as a member of Galmed’s board of directors since 2007. Mr. Nir serves as President and Chief Executive Officer of Tushia Consulting Engineers Ltd., and as Chairman of the Board of Directors of Matan Digital Printers Ltd. From 1998 to 2008, he served as President and Chief Executive Officer of Macpell Industries Ltd.
Between 1991 and 1998, Mr. Nir was Executive Vice President of Operations at Macpell Industries Ltd. and President and Chief Executive Officer of two of its subsidiaries: New Net Industries Ltd., and New Net Assets Ltd. Prior to 1991, Mr. Nir held management positions with Intel Corporation in Jerusalem, Israel and Tefen Management Consulting. Between 1999 and 2006, Mr. Nir served as Managing Partner at Spring Venture Capital Fund. He earned a B.Sc. in Industrial Engineering and Management from the Technion — Israel Institute of Technology in Haifa in 1989.

Marshall Heinberg

Mr. Heinberg has extensive experience relevant to the Company and insight into the global capital markets, and has worked with several life science and technology companies. Mr. Heinberg serves as a Senior Advisor to Burford Capital and is the founder and Managing Director of MAH Associates, LLC, which provides strategic advisory and consulting services to various companies, including the Company since 2013. Since April 2017, Mr. Heinberg has served on the board of directors of Ecology and Environment (NasdaqGM: EEI) and is currently Executive Chairman of the Board of Directors. Since January 2010, Mr. Heinberg has served on the board of directors of Universal Biosensors (UBI​.AX). Mr. Heinberg began his investment banking career in 1987 in the Corporate Finance Division of Oppenheimer & Co, Inc., which was acquired by Canadian Imperial Bank of Commerce (CIBC) in 1997. Mr. Heinberg served as Head of the Investment Banking Department and as a Senior Managing Director of Oppenheimer & Co. Inc. from 2008 until 2012, and as the U.S. Head of Investment Banking at CIBC World Markets from 2001 until 2008. Mr. Heinberg has also served as a director of National Financial Partners Corp., a business that provided advisory and brokerage services to corporate and high net worth individual clients in the United States and Canada until the company was acquired by Madison Dearborn in July 2013. Mr. Heinberg was also a non-​executive director of Image Entertainment, Inc., a leading independent licensee and distributor of enter­tainment programming in North America, until the Company was acquired in October 2012. Prior to joining Oppenheimer, Mr. Heinberg practiced corporate law for approx­i­mately four years. Mr. Heinberg has a B.S. in economics from the Wharton School at the University of Pennsylvania and a J.D. from Fordham Law School.

Back To Top